Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.
By M. Krebs, R. Sloane, L. Priest, L. Lancashire, Jian-mei Hou, A. Greystoke, T. Ward, R. Ferraldeschi, A. Hughes, G. Clack and 3 more. Journal of Clinical Oncology, 2011
861 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/8f9779b39334f433f81becd8f4c7b4e288c678bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “Encouraging results were also achieved for other tumor entities, including lung cancer (7, 8), bladder cancer (78, 79), head and neck cancer (40, 80, 81), testicular germ cell tumors (82), colorectal cancer (including stage II; refs.”
- Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. (2012, background): “In most cancers studied so far, CTCs are rarely detectable in early stages of disease, including NSCLC.(18) Here, CTCs were detected in 19 of 31 of patients with SCLC (61%) with limited disease stage (median, 1; range, 0 to 91; mean SD 11 22), and two CTM were detected in one of these patients.”